BioCryst Pharmaceuticals, Inc. (BCRX) Financial Statements (2024 and earlier)

Company Profile

Business Address 4505 EMPEROR BOULEVARD
DURHAM, NC 27703
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments410,670398,158424,310426,858417,483443,468
Cash and cash equivalents146,215155,136304,767246,899272,571395,504
Short-term investments264,455243,022119,543179,959144,91247,964
Restricted cash and investments1,5741,4631,4721,4441,4483,354
Receivables2,0711,0918,2683,0171,8431,932
Inventory, net of allowances, customer advances and progress billings27,03327,46627,53327,01923,37816,144
Inventory27,03327,46627,53327,01923,37816,144
Other undisclosed current assets69,70862,70554,91750,66350,70146,816
Total current assets:511,056490,883516,500509,001494,853511,714
Noncurrent Assets
Property, plant and equipment8,4388,3768,6178,4648,7028,799
Long-term investments and receivables 3,4453,43218,07734,332  
Long-term investments 3,4453,43218,07734,332  
Other noncurrent assets6,9467,0466,8066,7976,9837,207
Total noncurrent assets:18,82918,85433,50049,59315,68516,006
TOTAL ASSETS:529,885509,737550,000558,594510,538527,720
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities89,18981,466101,92177,88791,73577,465
Accounts payable13,8896,25414,3568,62212,02413,881
Accrued liabilities75,30075,21287,56569,26579,71163,584
Deferred revenue1,7791,2001,2241,5541,5211,471
Other undisclosed current liabilities2,5302,4912,3692,1962,1342,081
Total current liabilities:93,49885,157105,51481,63795,39081,017
Noncurrent Liabilities
Long-term debt and lease obligation293,176232,522231,624229,835150,714146,693
Long-term debt, excluding current maturities293,176232,522231,624223,867144,516140,236
Liabilities, other than long-term debt5,8035,9345,804   
Operating lease, liability5,8035,9345,8045,9686,1986,457
Total noncurrent liabilities:298,979238,456237,428235,803156,912153,150
Total liabilities:392,477323,613342,942317,440252,302234,167
Equity
Equity, attributable to parent(388,713)(328,287)(294,597)(242,659)(213,232)(164,215)
Common stock1,8951,8891,8791,8641,8591,856
Additional paid in capital1,191,9811,177,1921,158,1181,138,6541,125,4531,115,443
Accumulated other comprehensive income (loss)69058526(98)15186
Accumulated deficit(1,583,279)(1,507,953)(1,454,620)(1,383,079)(1,340,559)(1,281,700)
Total equity:(388,713)(328,287)(294,597)(242,659)(213,232)(164,215)
Other undisclosed liabilities and equity526,121514,411501,655483,813471,468457,768
TOTAL LIABILITIES AND EQUITY:529,885509,737550,000558,594510,538527,720

Income Statement (P&L) ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Revenues82,49168,77879,54575,82765,53249,923
Cost of revenue(950)(938)(2,496)(3,613)(247)(238)
Cost of goods and services sold(894)(931)(2,383)(3,543)(246)(236)
Gross profit:81,54167,84077,04972,21465,28549,685
Operating expenses(102,244)(96,255)(123,360)(89,659)(100,007)(99,642)
Operating loss:(20,703)(28,415)(46,311)(17,445)(34,722)(49,957)
Interest and debt expense(57,934)(27,396)(26,458)(24,775)(24,022)(23,837)
Loss from continuing operations before equity method investments, income taxes:(78,637)(55,811)(72,769)(42,220)(58,744)(73,794)
Other undisclosed income (loss) from continuing operations before income taxes4,0513,1491,3041,222741(123)
Loss from continuing operations before income taxes:(74,586)(52,662)(71,465)(40,998)(58,003)(73,917)
Income tax expense(740)(671)(76)(1,522)(856)(279)
Loss from continuing operations:(75,326)(53,333)(71,541)(42,520)(58,859)(74,196)
Loss before gain (loss) on sale of properties:(42,520)(58,859)(74,196)
Net loss available to common stockholders, diluted:(75,326)(53,333)(71,541)(42,520)(58,859)(74,196)

Comprehensive Income ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Net loss:(75,326)(53,333)(71,541)(42,520)(58,859)(74,196)
Other comprehensive income (loss)105559 (113)(171)9
Other undisclosed comprehensive loss   (151)   
Comprehensive loss:(75,221)(52,774)(71,692)(42,633)(59,030)(74,187)
Other undisclosed comprehensive income, net of tax, attributable to parent   275   
Comprehensive loss, net of tax, attributable to parent:(75,221)(52,774)(71,417)(42,633)(59,030)(74,187)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: